Login to Your Account

ODAC Gives Thumbs Up To Affymax' Peginesatide

By Marie Powers
Staff Writer

Thursday, December 8, 2011
After an afternoon of vigorous debate, members of the Oncologic Drugs Advisory Committee (ODAC) endorsed, by a 15-1 margin, the benefit/risk profile for peginesatide injection to treat anemia associated with chronic kidney disease (CKD) in adult patients on dialysis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription